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Introduction: Patients with stage IV non–small-cell lung cancer 
harboring an activating epidermal growth factor receptor (EGFR) 
mutation are eligible for treatment with EGFR tyrosine kinase inhibi-
tors. With pyrosequencing, low-frequency mutations may be detected 
more easily even in small diagnostic samples like endoscopic ultra-
sound-guided fine needle aspirations (EUS-FNA) and endobronchial 
ultrasound-guided transbronchial needle aspirations (EBUS-TBNA). 
The diagnostic performance of pyrosequencing in analyzing cytolog-
ical specimens is compared with the routinely used high-resolution 
melting (HRM) and Sanger sequencing.
Methods: Patients diagnosed with adenocarcinoma of the lung were 
selected from a fine needle aspiration and transbronchial needle 
aspiration specimen database. If formalin-fixed paraffin-embedded 
tumor blocks were available, mutation analysis was performed for 
EGFR and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
genes using both pyrosequencing and HRM. When HRM showed 
abnormalities, Sanger sequencing was used.
Results: A total of 126 samples were available for mutation analysis. 
The analysis success rate for pyrosequencing and HRM were 97% 
and 93%, respectively. HRM failures were observed in fragmented 
DNA showing chains of 100 to 200 bp. A significant correlation 
between length of DNA fragments (100–300 bp versus 300–400 bp) 
and mean sample age (797 versus 317 days) was found (p < 0.0001), 
suggesting an influence of sample age on DNA quality.
Conclusion: Pyrosequencing on cytological blocks, especially older 
tumor blocks, is feasible with a high diagnostic success rate. Failures 
in HRM were observed in DNA samples with short fragments related 
to longer storage times.
Key Words: Deoxyribonucleic acid mutational analysis, Endo-
scopic ultrasonography, Cytology, Non–small-cell lung cancer, 
DNA sequencing.
(J Thorac Oncol. 2013;8: 1012-1018)
A subset of the pulmonary adenocarcinomas (ACs) harbor-ing mutated epidermal growth factor receptor (EGFR) 
genes has a prolonged survival irrespective of treatment.1 
Mutations cause alterations in the intracellular part of the 
transmembrane EGFR. This results in a stronger binding of 
tyrosine kinase inhibitors (TKIs) than adenosine triphosphate 
(ATP) with subsequent inhibition of EGFR.2 When com-
pared with chemotherapy, treatment with EGFR-TKIs showed 
higher response rates and significant better progression-free 
survival with mild toxicity.1,3–6
This benefit in patients with activating EGFR mutations 
requires mutation analysis as a standard diagnostic procedure 
in patients with stage IV AC of the lung.
Another even more frequently encountered mutation in 
ACs of the lung occurs in the V-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog (KRAS) gene.
Recommendations on tissue and test characteristics 
for EGFR mutation analysis were recently published in an 
European consensus report.7 The authors prefer the use of 
histology and mention the possible mutation analysis in cyto-
logical specimens. In reported large clinical studies, mutation 
analysis is almost invariably performed on tissue samples.
In routine clinical practice tissue samples are required, 
however, a diagnosis is often made on cytological specimens. 
Tissue biopsies are not always available. Therefore, muta-
tion analysis of small tumor samples is necessary. Mutation 
analysis on cytological specimen, including transbronchial 
and transesophageal aspirates, has been previously reported in 
several studies.8–20 This is particularly relevant for the majority 
of stage III patients progressing to stage IV, enabling archived 
mediastinal aspiration cell blocks to be used for molecular 
processing. Those aspirates can be performed in the same 
lymph node in different directions gathering multiple aspi-
rates from different parts of the same node metastasis thereby 
increasing the yield of tumor cells.
Although it is not clear which method is the best for 
mutation analysis in non–small-cell lung cancer, a combina-
tion of DNA amplification and direct sequencing is the most 
practiced.
After DNA extraction, amplification of target sequences 
with the polymerase chain reaction (PCR) is the next step. 
Prescreening for abnormal target alleles is possible with 
high-resolution melting (HRM).21 The sensitivity of detect-
ing mutations can be increased by amplification refractory 
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mutation system polymerase chain (ARMS-PCR),22 allele-
specific PCR,23,24 peptide nucleic acid clamping methods,25,26 
or preferential amplification of mutant alleles with coampli-
fication at lower denaturation temperature–PCR technique.20
When genomic abnormalities are detected, further 
characterization with DNA sequencing follows. Various tech-
niques for sequencing have been developed. Test character-
istics have improved over time, and more recently developed 
tests require less tumor cells.
The question remains whether screening should pre-
cede sequencing or whether sequencing should be performed 
upfront. The diagnostic accuracy of tests in relation to the 
quality of samples as well as the costs and diagnostic speed 
are important factors in designing the optimal testing strategy.
Pyrosequencing is one of the latest assays using lumi-
nometric instead of electrophoretic detection.27 This technique 
enables characterization of mutations and quantification of 
mutated alleles in samples with low tumor cell density and 
detection with high accuracy rates.28
The objective of this study is to compare the diagnos-
tic performance of pyrosequencing with the comprehensive 
strategy of HRM (followed by Sanger sequencing29 in case 
of abnormalities) for EGFR and KRAS mutation analysis in 
paraffin-embedded cytological specimens of AC patients 
obtained with endoscopic-ultrasound– guided needle aspi-
ration (EUS) and endobronchial-ultrasound–guided needle 
aspiration (EBUS). The analysis success rates and concor-
dance rates for both techniques are determined.
PATIENTS AND METHODS
Patients
Patients with a cytological diagnosis of AC established 
on EUS- or EBUS-derived samples were selected from our 
local patient database. The diagnosis was based on morpho-
logic and immunohistochemical characteristics for all tumors.
All samples were coded and managed independently. 
The study was approved by the Medical Ethical Committee of 
the Isala Clinics in Zwolle, The Netherlands.
EUS and EBUS
EUS and EBUS was performed with Pentax ultrasound 
endoscopes (EUS FG-36UX respectively EBUS EB-1970UK; 
Pentax, Tokyo, Japan) with a Hitachi EUB-5500 processor 
(Hitachi, Tokyo, Japan). The fine-needle aspirations were per-
formed under conscious sedation with midazolam and with 
local anesthesia sprayed in the oropharynx (lidocain 1%) and 
lidocain gel 20 mg/ml. Needles of 22 gauge were used for 
sampling and at least two aspirates were smeared on slides 
initially. Aspirations per site (3–4 passes in different direc-
tions of the tumor or enlarged mediastinal lymph node) were 
performed and deposited in carbowax 2% fixative. Cell blocks 
were made using cell pellets embedded in AGAR 10%, fol-
lowed by formalin fixation, dehydration, and paraffinization.
Tumor Cell Density Estimation
Sections were cut from formalin-fixed paraffin-embed-
ded (FFPE) tissue blocks. The first and last sections were 
stained with hematoxylin and eosin for histopathological 
examination. The percentage of tumor cells is estimated using 
the first and last hematoxylin and eosin sections. The esti-
mated ratio is based on the tumor cell amount compared with 
stromal cells and lymphocytic background.
DNA Extraction
Genomic DNA was extracted from the remaining sec-
tions. The sections used for DNA extraction were deparaf-
finated and genomic DNA was extracted using the QIAamp 
DNA FFPE Tissue Kit (Qiagen, Venlo, The Netherlands) 
according to the manufacturer’s instruction. The extracted 
DNA was eluted in 100 µl ATE buffer.
DNA quality was checked by multiplex ladder PCR,30 
using 3µl Mastermix (500 µl 10× Gold buffer, 40 µl 100 mM 
Gene Amp dNTP Blend, 250 µl Glycerol 87%, 50 µl Cresol Red, 
300 µl 25 mM MgCl
2
, 360 µl double-distilled H2O [ddH
2
O]); 
5 µl primermix; 0,08 µl Amplitaq Gold (Applied Biosystems, 
Nieuwerkerk a/d IJssel, The Netherlands); 200 nM of each 
primer; 1,0 µl ddH
2
O and 1 µl sample per test. Primers used 
are listed in e-Table 1 (Supplemental Digital Content 1, http://
links.lww.com/JTO/A445). PCR cycling was performed on a 
Veriti 96-well Thermal Cycler (Applied Biosystems) using the 
following conditions, one 12-minute cycle at 94.4°C was fol-
lowed by 30 cycles of, respectively, 30 seconds at 95°C, 30 
seconds at 59°C, 45 seconds at 72°C, and finally one cycle of 
5 minutes at 72°C. The produced DNA amplicons were sepa-
rated using agarose gel electrophoresis (3% agarose gel; 200 
volt for 1 hour) and assessed with ultraviolet light.
Mutation Analysis
Exons 18, 19, 20, and 21 of the EGFR gene and exons 
2 and 3 of the KRAS gene were examined with HRM as pre-
viously described.21,31 HRM was performed in a total volume 
of 10 µl, containing 4 µl LightScanner mastermix (Idaho 
Technology Inc., Salt Lake City, UT), 2 µl genomic DNA, 2 
µl 100 nM of each primer, and 2 µl ddH
2
O. PCR cycling and 
HRM analysis were performed on a LightCycler 480II (Roche 
Diagnostics, Almere, The Netherlands) according to conditions 
previously described.32 When the HRM plots were abnormal 
HRM amplicons were checked with Sanger sequencing. HRM 
products were purified using ExoSAP-IT (GE Healthcare, 
Hoevelaken, The Netherlands) according to the manufacturer’s 
instruction. Primers used are listed in e-Table 2 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A446).
The purified HRM products were used for Sanger 
sequencing using the Big Dye Terminator v3.1 Kit (Applied 
Biosystems). The reaction mix consisted of 2 µl Sequencing 
RR-100, 3 µl 5x Sequencing buffer, 4 µl ddH
2
O, 1 µl purified 
PCR product, and 10 µl 2.5 µM M13 primer in a final volume 
of 20 µl.
The sequence reaction was run on a Veriti 96-well 
Thermal Cycler (Applied Biosystems) using the following 
conditions, one cycle of 96°C for 1 minute followed by 25 
cycles of 96°C for 10 seconds, 60°C for 125 seconds and 
at 4°C subsequently. The products were purified using the 
DyeEx 2.0 Spin Kit (Qiagen) according to the manufacturer’s 
instructions and run on a 3130 Genetic Analyzer (Applied 
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Biosystems). Afterward, the sequences were analyzed using 
the Sequencer 3.0 software (Applied Biosystems).
Pyrosequencing was performed using the PyroMark 
Q24 (Qiagen). The therascreen EGFR and KRAS Pyro Kits 
(Qiagen) were used according to the manufacturer’s instruc-
tion. The targeted sequences of EGFR and KRAS were ampli-
fied using PCR (Veriti 96-well Thermal Cycler; Applied 
Biosystems) using the following conditions, one 15-minute 
cycle at 95°C followed by 42 cycles of, respectively, 20 sec-
onds at 95°C, 30 seconds at 53°C, 20 seconds at 72°C, and 
finally one cycle of 5 minutes at 72°C. Each PCR product 
was used as a template. The sequencing primer hybridizes 
close to the sequence of interest. Pyrosequencing was per-
formed using PyroMark Gold Q96 reagents (Qiagen) con-
taining enzyme and substrate mixture, dATP-S, dCTP, dGTP, 
and dTTP. Nucleotide incorporation is followed by release 
of ATP. Luciferin and ATP generates light emission after a 
reaction catalyzed by luciferase. The unique dispensing order 
described by the manufacturer is used to detect possible muta-
tions in the targeted sequence. The pyrogram is analyzed using 
the pyrosequencing data analysis software (Qiagen).
Costs of Materials and Handling Time
The costs of materials to run a single sample for HRM, 
Sanger sequencing, and pyrosequencing are $100, $355, and 
$700, respectively. If possible, costs can be reduced by ana-
lyzing up to two patient samples per run for EGFR exon 18 
to 21 and KRAS exon 2 to 3 ($520 per patient for 2 cases 
including blanc controls). The time required for a laboratory 
technician to perform a single HRM analysis is 50 minutes. 
When Sanger sequencing follows HRM the total handling 
time is 90 minutes. Pyrosequencing takes 100 minutes, and 
the total time required for HRM followed by pyrosequencing 
is 150 minutes.
Statistical Analysis
Patient characteristics were examined with descrip-
tive statistics. A Pearson’s correlation coefficient was used to 
assess the association between estimated tumor density and 
allele frequency. The difference in mean sample age between 
base pairs categories 100 to 300 and 300 to 400 was analyzed 
using an unpaired Student’s t test.
RESULTS
Patient Samples
Between June 2008 and September 2011, pulmonary AC 
was diagnosed in 169 patients by different pathologists using 
EUS-fine needle aspiration (n = 90) or EBUS-transbronchial 
needle aspiration (n = 79).
After reviewing the slides for study purposes the diag-
noses changed to a different pathologic classification in five 
patients. For all other patients (n =164) there was an enquiry 
for adequate tumor material in deposit. From 24 patients 
no agar-embedded material was stored, and from 13 other 
patients no DNA was available (see also Fig. 1).
In six patients DNA had been isolated previously and 
was not available anymore. FFPE tissue blocks did not contain 
material to redo the DNA extraction after the first extraction 
and immunohistochemical analysis. HRM had been per-
formed in the samples of all of these patients followed by 
Sanger sequencing in three cases. There were five EGFR and 
KRAS wild type and one EGFR exon 19 deletion.
Tumor samples of 126 patients were processed for DNA 
analysis. Patient characteristics, including disease stages, are 
described in Table 1. Amplification was not successful in 4 of 
126 patients, resulting in 122 samples that were further ana-
lyzed with both HRM and pyrosequencing.
Because of insufficient DNA quality in five samples, 
HRM was unsuccessful (HRM for both EGFR and KRAS failed 
in 3 patients and HRM for EGFR alone failed in 2 patients). In 
39 of 117 (33%) patients, HRM showed abnormalities in the 
EGFR exons and in 50 of 119 (42%) patients, HRM showed 
abnormalities in the KRAS exons. In these patients direct 
sequencing was performed to confirm or exclude mutations. 
In 24 patients, abnormalities in more than one gene were 
detected and required multiple Sanger sequencing tests.
Mutations
Table 2 shows the results of pyrosequencing for EGFR 
and KRAS in EUS and EBUS samples. In 122 samples of 
AC, 15 EGFR mutations (12%; 12 activating and 3 inhibiting 
mutations) and 51 KRAS mutations (42%) were detected.
Detection Rate and Tumor 
Analysis Success Rate
The detection rate of pyrosequencing for EGFR and 
KRAS mutations was 122 of 122 (100%), and the tumor 
analysis success rate was 97% (122 of 126) for both genes. 
The detection rate for EGFR mutations in all endosonogra-
phy-guided samples with HRM in combination with Sanger 
sequencing was 117 of 122 (96%), and the tumor analysis suc-
cess rate 93% (117 of 126).
Sanger sequencing for EGFR and/or KRAS genes after 
HRM was performed in 76 of 119 samples showing single-
nucleotide polymorphisms (SNPs) in 19 samples when HRM 
was abnormal for exons 18 (n = 11) and 21 (n = 8). Detection 
of SNPs is relatively high because of the chosen primer sets, 
which include a common SNP18 hotspot. The SNP rate for 
exon 18 could be reduced by using different primer sets.
For KRAS the analysis success rate was 94% (119 of 
126). Abnormalities detected with HRM in codons 12, 13, and 
61 were all based on mutations.
Concordance Rates
For EGFR mutation analysis, HRM with Sanger 
sequencing in case of HRM abnormalities and pyrosequenc-
ing showed a concordance rate of 100% (117 of 117). For 
KRAS mutation analysis the concordance rate was 98% (117 
of 119). In two patients pyrosequencing revealed a G12C 
point mutation that was not discovered with HRM.
Tumor Cell Density
The mean estimated tumor density in samples with 
mutations was 35.5% (range, 5–90%). The mean frequency of 
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the mutated alleles provided by the pyrosequencing software 
was 38.7% (range, 5.7–89.3%). The estimated tumor density 
and the frequency of mutated alleles were well associated 
(Pearson’s correlation coefficient of 0.57 [p < 0.001]).
Factors Influencing Test Results
The quality of DNA, expressed as the length of base 
pairs was studied with agarose gel electrophoresis of PCR 
products. Shorter DNA chains indicate more fragmenta-
tion. All patients were classified into two subgroups with 
DNA of 100–300 bp and 300–400 bp showing mean sample 
ages of 784 days and 354 days, respectively (p < 0.0001). 
All five HRM failures showed short DNA fragments 
(100–200 bp).
The estimated tumor cell density in five samples, which 
proved to be inadequate for HRM analysis, was 5% (n = 1), 
10% (n = 1), 30% (n = 2), and 50% (n = 1). In the four samples 
with an amplification failure, the estimated tumor cell densi-
ties were 5% (n = 1), 10% (n = 2), and 60% (n = 1).
FIGURE 1.  Flow chart showing the selection of patient samples and the successive stages of processing and analysis performed 
on them. EGFR, epidermal growth factor receptor; HRM, high-resolution melting; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral onco-
gene homolog gene.
TABLE 1.  Characteristics of 126 Patients Eligible for DNA 
Processing
Age, Average (Range), yr 66 (26–85)
Sex
  Male 65
  Female 61
EUS: EBUS 63:63
Tumor stage
  1b 2
  2a 4
  2b 2
  3a 63
  3b 12
  4 43
Mean sample age in days (range) 585 (2–1323)
Mean tumor cell content (range) 30% (5–90)
EBUS, endobronchial ultrasound; EUS, endoscopic ultrasound.
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DISCUSSION
In this study, the diagnostic performances of two 
sequencing strategies were compared on cytological samples 
from mediastinal lymph node metastases in patients with 
AC. Pyrosequencing was compared with HRM followed by 
Sanger sequencing for EGFR and KRAS mutations in speci-
mens obtained by EUS and EBUS. Pyrosequencing on cyto-
logical blocks, especially older tumor blocks, is feasible. The 
diagnostic performance of both tests was good. HRM failed in 
a few samples in which the DNA was degraded as a result of 
longer sample storage times.
Diagnostic Success Rates
The high diagnostic success rates of both pyrosequenc-
ing (97%) and HRM (93%) in this study confirm that cytologi-
cal aspirates from EUS and EBUS are suitable for molecular 
analysis. In a few samples we were unable to yield DNA with 
sufficient quality for HRM and pyrosequencing. After DNA 
amplification, HRM failed in a few more samples as well. In 
contrast to HRM analysis, pyrosequencing was successful in 
all samples, indicating a better sensitivity.
EGFR mutation analysis has been performed previ-
ously on various kinds of cytological samples such as pleural 
effusion cell blocks, percutaneous aspirates,8,15,33 pericardial 
effusion and bronchoalveolar lavage,9 and also EBUS-8–10,12,14–
16,19,33,34 and EUS-guided aspirates.14,16,33 Reported success 
rates of mutation analysis on EUS-guided or EBUS-guided 
fine-needle aspirates ranged from 72% to 99% in previous 
studies.8,9,11,12,14,16,17,20
A comparison of the diagnostic performance of pyro-
sequencing with other sequencing techniques is difficult. In 
contrast to our study, samples in previous studies were often 
selected on estimated tumor density, and most studies were 
prospective studies and consequently used relatively younger 
specimens.
Concordance Rates
In all but five patients with amplifiable DNA, HRM 
could be performed. The concordance between pyrosequenc-
ing and HRM was 100% for EGFR and 98% for KRAS. Two 
samples showed wild-type KRAS using HRM analysis, but 
turned out to be KRAS mutated after pyrosequencing. This 
finding is likely related to the higher test sensitivity.
Two previous reports compared different sequencing 
methods but none described pyrosequencing. A recent study of 
49 cytological samples of bronchial brushings and pleural effu-
sions compared five different sequencing tests (PCR-Invader, 
peptide nucleic acid-locked nucleic acid PCR clamp, direct 
sequencing, Cycleave, and Scorpion ARMS).18 Concordance 
rates among different methods ranged from 93.1% to 100% 
(bronchial brushings) and 85% to 100% (pleural effusions). In 
a report on 94 patients, Sanger sequencing was less sensitive 
for detecting EGFR mutations than (ARMS).10
Tumor Cell Density
In this study a significant, although modest, correlation 
was found between the estimated tumor cell density and the 
allele frequency of different EGFR and KRAS mutations.
Previous studies used predefined cutoff values of tumor 
cell density to consider samples suitable for molecular analy-
sis.8,13,16,33 The cutoff values ranged from 25%33 to 70%.13 In one 
report, authors claimed that as little as eight tumor cells from 
paraffin-embedded or fresh specimens obtained after microdis-
section were considered sufficient for mutation analysis in vari-
ous cytological specimens.9 Other studies on molecular analysis 
of cytological samples described no cutoff values at all.10–12,15,18 
Estimation of tumor cell percentages is not as relevant as previ-
ously stated. Moreover, tumor content is a subjective measure 
with interobserver variation. Finding a mutation in a sample 
with very low tumor density is considered a true-positive find-
ing. However, the finding of a wild type in a very low tumor-
density sample could result in a false-negative interpretation of 
a present mutation. In addition to this technical issue the ques-
tion remains whether these very low-frequency mutations are 
clinically significant. Are they drivers or bystander mutations?
Sample Age
A relationship was demonstrated between sample age 
and DNA chain lengths after PCR. All HRM failures showed 
short DNA fragments in the ladder PCR, suggesting a rela-
tionship between sample age and successful molecular analy-
sis. Nevertheless, we found only a few samples unsuitable for 
TABLE 2.  Mutations Found in EUS- and EBUS-Guided Fine-Needle Aspirations of 122 Patients with Pyrosequencing Technique
EGFR Mutations KRAS Mutations
n n
Exon 19 delE746-A750 4 (27%) Exon 2 G12C 24 (47%)
Exon 19 delL747-P753insP 1 (7%) Exon 2 G12A 8 (16%)
Exon 20 T790M 3 (20%) Exon 2 G12V 7 (14%)
Exon 21 L858R 7 (47%) Exon 2 G12D 6 (12%)
Exon 2 G12R 1 (2%)
Exon 3 G13C 1 (2%)
Exon 3 G13D 3 (6%)
Exon 3 Q61H 1 (2%)
Total 15 51
EGFR, epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog gene.
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molecular analysis, despite long storage times for up to 3.5 
years.
This observation is relevant in case of using archival 
cytological specimen. Subtyping and staging is frequently 
performed at once in stage III non–small-cell lung cancer by 
EUS or EBUS. However, there is no clinical reason to ana-
lyze the mutation status in stage III disease because treatment 
with TKIs is not indicated according to present insights. Most 
patients with stage III disease, however, progress to stage IV 
during follow-up. When adequate material is available for 
these patients, samples can easily be reprocessed for molecu-
lar analysis without new invasive tests.
Pyrosequencing in Relation to Other Assays
The high concordance rate between HRM and pyrose-
quencing demonstrates the value of both tests for DNA analy-
sis of EUS- and EBUS-derived samples. Because previous 
reports selected samples based on tumor cell percentages and 
were obtained from different sites with various sampling tech-
niques, comparison with other methods is difficult. In con-
trast to previous studies, this study used samples derived from 
archival tissue with suboptimal (fragmented) DNA.
Comparable diagnostic performances for EGFR and 
KRAS mutation analysis, however, were described with coam-
plification at lower denaturation temperature–PCR in combi-
nation with Sanger sequencing in EBUS samples, enabling the 
detection of mutation frequencies as low as 5% to 10%.20
Tumor percentages in the same range of 5% to 10% 
allowed for mutation detection in our study as well although 
there is some doubt to call a sample a wild type when no 
mutations are detected in these samples. With pyrosequenc-
ing, analysis in samples with tumor percentages below 5% is 
feasible and can be used to confirm HRM analysis.
Other features, particularly cost aspects, are important 
to accomplish the comparison between pyrosequencing and 
other methods.
Financial Considerations
The least expensive method is HRM combined with 
Sanger sequencing. Pyrosequencing is too expensive to be used 
as a routine method in daily practice. The financial gap between 
HRM followed by Sanger sequencing and pyrosequencing is 
irreconcilable, even when more patient samples are analyzed 
in one run. More relevant is the comparison of costs between 
HRM prescreening followed by Sanger sequencing and HRM 
prescreening followed by pyrosequencing. A 38% increase in 
expenses was calculated for the latter option.
The difference in costs when Sanger sequencing is 
replaced by pyrosequencing for samples with an abnormal 
HRM, is substantial; nevertheless, replacement of Sanger 
sequencing by pyrosequencing does have considerable advan-
tages (described below) that compensate the surplus of costs 
to some extent.
The Position of Pyrosequencing 
in Mutation Analysis
Sanger sequencing is performed on amplified DNA 
after HRM analysis. Failure of the HRM, because of poor 
DNA quality, will consequently result in a failure of Sanger 
sequencing as well.
Identification of mutations with pyrosequencing, if the 
HRM melting curve and difference plots show deviations 
from the wild-type curves, could serve as an alternative for 
Sanger sequencing. An important advantage of such a com-
bined approach is that the molecular analysis is based on two 
independent techniques, allowing for a more confident molec-
ular diagnosis.
The high sensitivity of pyrosequencing enables detec-
tion of low-frequency mutations and analysis in samples with 
a low tumor content or fragmented DNA. Sample characteris-
tics such as tumor cell percentage, older sample age, and short 
DNA fragments in the ladder PCR (e.g., <200 bp), could serve 
as criteria to choose pyrosequencing over Sanger sequencing.
RESULTS OF MUTATION ANALYSIS
The EGFR mutation incidence was 12%, and is some-
what lower when compared with large European series (14%–
16.6%).3,35 In contrast, the incidence of KRAS mutations in 
this study (42%) is considerably higher compared with a large 
French study (14%). The difference in mutation incidence is 
likely the result of patient selection. The French study was 
performed nationwide, and consisted of stage IV patients. Our 
study population was derived from a relatively small rural area 
and includes stage III and IV patients. In a previous study from 
The Netherlands a comparable incidence for KRAS mutations 
(37%) and an even lower incidence for EGFR mutations (7%) 
has been described.14
LIMITATIONS
Important for the patient is a fast diagnostic track to 
allow a treatment start as soon as possible. Performing HRM 
as an initial screening step is a swift method to separate wild-
type samples from mutated samples. The disadvantage is that 
this method requires a few days more when HRM abnormali-
ties have to be determined by sequencing (in this study 65% of 
patients) in contrast to the use of pyrosequencing as the initial 
screening method.
CONCLUSION
Mutation analysis in EUS- and EBUS-guided needle 
aspirates using pyrosequencing is feasible and showed a high 
diagnostic success rate. The use of cytological specimens did 
not lead to analytical difficulties, and mutation frequencies 
were similar to known EGFR and KRAS mutation frequen-
cies in our population. When comparing pyrosequencing with 
HRM, a high concordance rate was found. All HRM failures 
were observed in samples with fragmented DNA associated 
with longer storage times of the FFPE cell blocks. Mutation 
analysis by pyrosequencing enables the use of shorter DNA 
fragments, increasing the yield of molecular analysis on older 
and less optimal tissue samples.
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